The studies, headed by Martin Blaser, M.D., director of the Human Microbiome Program at New York University (NYU) School of Medicine, found that giving very young diabetes-predisposed mouse pups a single, 5-day therapeutic course of antibiotics resulted in “deep and persistent” effects on the intestinal microbiome, which accelerated and enhanced T1D development.